Abstract
Ms. Christine Cissy White received a diagnosis of high-grade serous ovarian cancer in August 2019 at 52 years of age. She had debulking surgery with minimal residual disease and completed frontline chemotherapy with carboplatin and paclitaxel. In 2020, she enrolled in the ATHENA clinical maintenance trial of rucaparib with or without nivolumab versus placebo. Later that year, her tumor recurred, but her treatment allocation during that clinical trial remains undisclosed. In 2021, she had another line of chemotherapy with carboplatin and liposomal doxorubicin, but her tumor recurred. In 2022, she enrolled in a clinical trial for approximately 3 months (ClinicalTrials.gov number, NCT03564340), at which time her disease progressed. She had a short course of radiation treatment to shrink a cancerous lymph node in June 2022; she is now receiving an ipilimumab and nivolumab immunotherapy combination.In this Patient Platform, Christine Cissy White relays her experiences with ovarian cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
